|
|
Volumn 104, Issue 1, 2012, Pages 14-15
|
|
Challenges ahead for companion diagnostics
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
B RAF KINASE;
CETUXIMAB;
CRIZOTINIB;
ERLOTINIB;
IMATINIB;
TRASTUZUMAB;
VEMURAFENIB;
CANCER CENTER;
CANCER CHEMOTHERAPY;
CLINICAL DECISION MAKING;
COMPANION DIAGNOSTIC TEST;
DIAGNOSTIC ACCURACY;
DIAGNOSTIC TEST;
DRUG INDICATION;
DRUG INDUSTRY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LUNG NON SMALL CELL CANCER;
MELANOMA;
MUTATIONAL ANALYSIS;
NOTE;
PATIENT SELECTION;
PERSONALIZED MEDICINE;
PRIORITY JOURNAL;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DIAGNOSTIC TEST APPROVAL;
DRUG APPROVAL;
DRUG LABELING;
HUMANS;
INDIVIDUALIZED MEDICINE;
INDOLES;
MELANOMA;
MOLECULAR TARGETED THERAPY;
MUTATION;
NEOPLASMS;
PATIENT SELECTION;
PYRAZOLES;
PYRIDINES;
SULFONAMIDES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84855484207
PISSN: 00278874
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djr535 Document Type: Note |
|
Times cited : (11)
|
|
References (0)
|
